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Serotonin (5-HT) has been hypothesized to be implicated in performance monitoring by promoting behavioral inhibition in the face of
aversive events. However, it is unclear whether this is restricted to external (punishment) or includes internal (response errors) events.
The aim of the current study was to test whether higher 5-HT levels instigate inhibition specifically in the face of errors, measured as
post-error slowing (PES), and whether this is represented in electrophysiological correlates of error processing, namely error-related
negativity (ERN) and positivity. Therefore, froma large sample of human subjects (n 878), two extreme groupswere formed regarding
hypothesized high and low 5-HT transporter (5-HTT) expression based on 5-HTTLPR and two additional single nucleotide polymor-
phisms (rs25531, rs25532). Seventeen higher (LL) and 15 lower (SS) expressing Caucasian subjects were administered the selective
serotonin reuptake inhibitor (SSRI) citalopram (10 mg) intravenously in a double-blind crossover design. We found pharmacogenetic
evidence for a role of 5-HT inmediating PES: SSRI administration increased PES in both genetic groups, and SS subjects displayed higher
PES. These effects were absent on post-conflict slowing. However, ERN and error positivity were unaffected by pharmacogenetic factors,
but ERN was decoupled from behavioral adaptation by SSRI administration in the LL group. Thus, pharmacogenetic evidence suggests
that increased 5-HT levels lead to behavioral inhibition in the context of internal aversive events, but electrophysiological correlates of
performancemonitoring appear unrelated to the 5-HT system. Therefore, our findings are consistent with theories suggesting that 5-HT
mediates the link between aversive processing and inhibition.
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Introduction
Serotonin (5-HT) has been implicated in the modulation of di-
verse neurocognitive functions (Lucki, 1998), and considerable
attention has been paid to its role in behavioral inhibition and
processing of aversive events. It has been reported repeatedly
that, in the face of expected punishment, a reduction of 5-HT
levels leads to a disinhibition of behavior (Soubrie´, 1986; Crock-
ett et al., 2009) such that 5-HT facilitates avoidance of detrimen-
tal actions. Such functions are controlled by a performance
monitoring network, yet neural evidence for serotonergic in-
volvement in these abilities is sparse.
The error-related negativity (ERN) and error positivity are
EEG potentials thought to reflect early detection and evaluation
of evidence for an erroneous response by a performance moni-
toring network originating in the anterior midcingulate cortex
(aMCC; Steinhauser and Yeung, 2010; Ullsperger et al., 2014).
After errors, subjects usually slow down their responses and in-
crease their accuracy, a phenomenon known as post-error slow-
ing (PES; Rabbitt, 1966). Single-trial ERN amplitudes have been
shown to covary with the amount of slowing induced by errors,
suggesting a direct link between error detection and adaptive
implementation (Debener et al., 2005). Furthermore, after re-
sponse conflict, subjects also show reaction slowing, which has
been termed post-conflict slowing (PCS; Ullsperger et al., 2005;
Verguts et al., 2011). Although PES involves the evaluation of a
subjectively aversive event, this is not the case for PCS.
It is currently unclear whether 5-HT-mediated inhibition re-
lies on this performance monitoring network or whether it is
mediated in other ways, possibly subcortically. The main ap-
proach to study effects of neuromodulatory systems on human
behavior are either pharmacological or genetic association stud-
ies, both of which have yielded mixed results. Some genetic stud-
ies suggest that higher 5-HT levels caused by a polymorphism
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(5-HTTLPR) at the 5-HT transporter (5-HTT) gene (SLC6A4)
covary with increased neuronal performance monitoring indices,
such as the ERN (Fallgatter et al., 2004), which then may lead to
increased inhibition (Holmes et al., 2010); however, data are incon-
sistent (Olvet et al., 2010). Conversely, pharmacological challenges
within the 5-HT system are complicated by the considerable degree
of individual genetic variance (Veenstra-VanderWeele et al., 2000).
Thus, well controlled pharmacogenetic studies are highly desirable
to elucidate the role of 5-HT in performancemonitoring functions.
The aim of the current study was to systematically examine
effects of an acute selective pharmacological challenge and
genetic variations of the 5-HT system on PES, PCS, and the elec-
trophysiological correlates of error processing, including the
single-trial coupling between ERN and PES. We used an acute
blockade of 5-HTTs via the intravenous application of a selective
serotonin reuptake inhibitor (SSRI) in a double-blind crossover
design in human subjects. The genetic background was con-
trolled for by an extreme group approach: from a large sample of
genotyped Caucasian subjects (n  878), two groups based on
estimated highest (LL; n  17) and lowest (SS; n  15) 5-HTT
expression were selected (Hu et al., 2006). We hypothesized in-
creased PES (Crockett et al., 2012) andnot PCS in S allele carriers,
because PES involves evaluation of subjectively aversive events
(Boureau and Dayan, 2011). Because SSRIs increase extracellular
5-HT akin to the hypothesized difference between S and L allele
carriers (Murphy et al., 2008), we furthermore expected in-
creased PES after drug administration. If this effect is mediated
via increased performance monitoring activity in the aMCC, ac-
companying increases in ERN and error positivity and/or cou-
pling of these potentials and following behavioral adaptationwould
be expected. In contrast, differential modulation and decoupling of
error-related potentials and PES would indicate 5-HT-independent
routes of the error signal to aMCC-based performance monitoring
and post-error motor inhibition.
Materials andMethods
Participants. Of 878 subjects that had been genotyped for 5-HTTLPR
polymorphisms, homozygous S and L Caucasian subjects were invited to
participate in the current study. Thirty-four subjects (23 females) were
included after a second genotype analysis for rs25531 and rs25532 had
been performed for LL subjects (see below). Exclusion criteria were any
reported history of psychiatric or neurological disorders, drug abuse,
more than moderate alcohol (24 units/week) or nicotine (more than
four cigarettes per day) consumption, and age18 or35 years. Preg-
nancy was ruled out by measuring human chorionic gonadotropin-
(0.1 U/L) in blood samples from female subjects 2 d before each test
session to exclude possible fetal risks. The drug was well tolerated, but
one subject experienced side effects (nausea and vomiting) and was ex-
cluded from the study. Another subject was excluded during the first
(placebo) test session because of an inability to follow task instructions.
Thus, the final sample consists of 17 LL and 15 SS subjects. For one
subject, EEG recording failed during one session and is thus excluded
from EEG analysis. All procedures were conducted in accordance with
the principles of the Declaration of Helsinki, and the study has been
approved by the ethics committee of the Medical Faculty of the Univer-
sity of Cologne (Cologne, Germany).
Genotyping. Genotyping was performed in a two-step sequence. First,
of a database of already genotyped subjects (n 878), only homozygous
L (n 278) and S (n 156) allele carriers were invited to participate in
the pharmacological study. This sample included 444 LS carriers and
thus was in Hardy–Weinberg equilibrium (p  0.354 for violation).
Genotyping was done using automated purification of genomic DNA
conducted by means of the MagNA Pure LC System using a commercial
extraction kit (MagNA Pure LC DNA isolation kit; Roche Diagnostics).
The 5-HTT region was amplified by PCR (Mastercycler). Primer se-
quences were 5-TCCTCCGCTTTGGCGCCTCTTCC-3 and 5-TGGG
GGTTGCAGGGGAGATCCTG-3. After an initial denaturation for 6
min at 94°C, 37 cycles of denaturing at 94°C for 30 s, annealing at 64°C for
1.5 min, and extension at 72°C for 1 min were followed by a final exten-
sion at 72°C for 5 min. PCR amplification was performed in a final
volume of 25 l consisting of 50 ng of genomic DNA, 0.2 mM of each
deoxyribonucleotide, 0.5M sense and antisense primers, 2.5mMMgCl2,
5.3% dimethyl sulfoxide, 1 U of Diamond Taq polymerase (Eurogentec),
and the buffer of the enzyme supplier. For genotyping, samples were
loaded onto a 1.6% agarose gel in a tris-borate-EDTA solution, run for
1 h 20 min at 170 V, and visualized by etidiumbromide under UV light.
Samples were visualized and genotyped by at least two independent
raters.
A possible problem of studies on the 5-HTTLPR is the presence of two
additional single nucleotide polymorphisms (SNPs) that modulate
5-HTT expression on top of the 5-HTTLPR repeat polymorphism.
rs25531 (AG) and rs25532 (CT) have been identified and,whennot
controlled for, can lead to 5-HTT expression levels for the L allele similar
to those seen for the S allele (Hu et al., 2006; Wendland et al., 2008).
Therefore, to maximize hypothesized group differences in 5-HTT ex-
pression, we analyzed these two additional SNPs in all L/L allele carriers
and excluded low expressing genotypes. Thiswas done by direct sequenc-
ing of similarly obtained PCR products as mentioned above. After enzy-
matic purificationwith exonuclease I and alkaline phosphatase with both
amplification primers, sequences were analyzed using SeqMan DNA-
Star software (Lasergene). L/L subjects who were not homozygous for
both higher expressing forms at rs25531 (A) and rs25532 (C) were ex-
cluded; thus, the LL group comprises 17 carriers of the in vitro highest
expressing LAC/LAC genotype (Wendland et al., 2008), and the SS group
comprises 15 homozygous carriers of the S allele (Fig. 1A).
Study procedure and data acquisition.When arriving at the laboratory,
all participants completed a clinical interview with the physician in
charge, filled in baseline questionnaires (Table 1), and completed visual
analog scales (VASs; Bond and Lader, 1974) to asses mood changes.
Thereafter, in double-blind manner, either 10 mg of citalopram (Cip-
ramil) diluted in saline (250ml) or saline alone were administered intra-
venously over a period of 30 min (Fig. 1B). The order of administration
was counterbalanced. Plasma levels of intravenous citalopram have been
shown to remain constant over4 h (Lotrich et al., 2004). On average,
subjects performed the task 85 min after completion of the infusion
(range, 50–125 min), which depended on the time necessary to mount
EEG caps and execute other tasks. After the infusion was completed,
elastic EEG caps (Easycap) with 60 Ag/AgCl sintered electrodes were
mounted in the extended 10–20 system with impedances kept below 5
k. Data were recorded continuously at a 500 Hz sampling rate with
BrainAmp MR plus amplifiers (Brain Products) and analyzed offline
using EEGLAB 12.0 (Delorme andMakeig, 2004) and custom code writ-
ten in MATLAB 2012b (MathWorks). Electrodes at the left and right
outer canthus and above and below the left eye captured eyemovements.
The ground electrode was positioned at F2; data were online referenced
to CPz and offline re-referenced to common average. The EEG task was
performed while subjects were seated in a dimly lit, acoustically and
electromagnetically shielded chamber. Additional other tasks were per-
formed, and data of these will be reported elsewhere. Test sessions were
separated by at least 7 d to allow complete washout of the drug, and all
female subjects were reinvited for the second session at the same time
point in their menstrual cycles as the first session had taken place (i.e.,
following multiples of 25–31 d) to reduce hormonal fluctuations.
Flanker task. A speeded version of the Eriksen flanker task was used.
Subjects had to respond in accordance with the direction of a centrally
presented arrow (target) and to ignore four flanking arrows (flankers)
that appeared earlier on the screen with a stimulus onset asynchrony of
80ms (Fig. 1C). All stimuli stayed thereafter together on screen for 30ms.
On congruent trials, central and flanking arrows pointed to the same
direction, whereas on incongruent trials, both pointed into different di-
rections, inducing the tendency to respond to the direction of the flanker.
Subjects were instructed to respond as fast and accurately as possible. A
random intertrial interval (ITI) was used that varied between 1100 and
2000 ms. Every 100 trials, subjects received written feedback on screen
8182 • J. Neurosci., May 27, 2015 • 35(21):8181–8190 Fischer et al. • Serotonergic Modulation of Performance Monitoring
about their performance and whether they should speed up their re-
sponses. Subjects were told to speed up their responses if the number of
errors committed in the incongruent condition was below 20%. Addi-
tionally, the screen was bordered by a colored frame that encouraged
subjects to speed up their responses by changing the color from green to
red with a delay of 12 trials when they did not commit enough errors.
Each subject completed 492 trials, of which half were incongruent. The
number of switches from one required response direction to the other,
the total number of required responses with the left or right hand in
congruent and incongruent condition, and the trial sequence between
congruent and incongruent trials were exactly counterbalanced. Be-
fore the task began, all subjects completed 21 training trials on each
test day.
After each session, subjects had to indicate whether they got angry
when committing an error on a scale from 1 (not at all) to 10 (very).
Average scores were 6.7  0.3, suggesting that subjects experienced er-
rors as aversive, and reports were not different between genetic or drug
conditions [mixed linear model (MLM), all p values0.70].
EEG analysis. The signal was bandpass filtered from 0.5 to 42 Hz, and
epochs spanning from 2 s before to 1.5 s after response onset were ex-
tracted. Erroneous and correct trials were corrected separately for arti-
facts and epochs that contained deviations 5 SDs of the mean
probability distribution of each condition were automatically rejected.
This was done so not to confuse the sometimes very high single-trial ERN
amplitudes with artifacts, and no more than 5% of the trials in each
conditionwere removed. Epoched datawere demeaned and submitted to
adaptive mixture independent component analysis (Palmer et al., 2012).
Independent components reflecting uniform artifacts, such as eyeblinks,
were removed from the data, and baseline correction from 300 to 100ms
before response onset was applied. Average and grand-average wave-
forms were then calculated, and event-related potential (ERP) data were
measured as described in the corresponding results.
To establish the relationship between early correlates of error process-
ing and PES, multiple robust single-trial regression analysis was used
(Cohen and Cavanagh, 2011; Fischer and Ullsperger, 2013; Ullsperger et
al., 2014). The regression model used the reaction time (RT) of the fol-
lowing trials for all error trials as the dependent variable, whereas EEG
activity and following congruency were used as predictor variables in-
cluding their interaction. Here, all trials in which subjects corrected their
response with another button press were excluded. Single-trial data were
smoothed with a running average of 10 ms before and after each data
point and calculated for each data point between 	250 and 500 ms
surrounding the response at electrode FCz. Robust regression coeffi-
cients were scaled by their SDs and are thus comparable across subjects.
We used a cluster-based permutation test to correct for multiple com-
parisons in the time window of interest (0–500 ms) by randomly multi-
plying regression weights over subjects with 	1 in 5000 iterations. The
resulting distribution of the highest sums of t values within resulting
clusters of significant effects (threshold   0.025) found per iteration
were then used to determine p values for the observed effects (Maris and
Oostenveld, 2007).
Statistical analyses. MLMs were used to test main effects of factors
drug, genotype, and their interactions (Gueorguieva andKrystal, 2004) if
not stated otherwise. An additional factor coding the current session
(first or second) was introduced to account for training effects attribut-
able to task repetition and the previously reported possible dependence
of serotonergic drug effects on order of administration (Murphy et al.,
2002). Thus, ourmain analysis consists of anMLM for the comparison of
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Figure1. Studydesignand task structure.A,B, Studydesignand time schedule of drugadministrationand task conduction.C, The timingof the flanker taskwith congruent and incongruent trials
shown separately. SOA, Stimulus onset asynchrony.
Table 1. Demographics and characteristics of the sample
LL (n 17) SS (n 15) p for difference
Genetics
5-HTTLPR Homozygous long Homozygous short
rs25531 A/A
rs25532 C/C
Demographics
Gender (females/males) 12/5 10/5
Age 23.8 0.5 23.9 0.9 0.920
Weight 67.8 2.1 65.7 0.7 0.518
Verbal IQ 105.8 10.1 110.8 9.0 0.154
Questionnaires
BDI-II 2.85 0.7 4.03 0.8 0.300
EPQ-RS neuroticism 2.94 0.61 4.73 0.67 0.056
EPQ-RS psychoticism 2.59 0.33 3.2 0.47 0.288
EPQ-RS extraversion 9.24 0.71 8.07 0.87 0.302
EPQ-RS lie scale 2.76 0.50 0.4 0.13  0.001
BIS-11 total 62.3 2.2 65.4 2.1 0.306
BIS attentional 15.6 0.6 16.4 0.7 0.410
BIS motor 23.5 0.8 24.1 0.7 0.544
BIS nonplanning 23.2 1.4 25.5 1 0.187
Group LL included only the high expressing homozygous LAC genotype; group SS included C and T variants at
rs25532. Groups did not differ with regard to demographics, IQ, and baseline depression scores. A significant differ-
ence was observed on the lie scale of the EPQ-RS, indicating higher scores of social desirability in the LL group.
Additionally, a trend toward higher neuroticism scores was seen in group SS, which is in accordance with previous
studies (Schinka et al., 2004). Impulsiveness measured with the BIS-11 did not show group differences. Values
represent mean SE. BDI, Beck Depression Inventory; EPQ-RS, Eysenck Personality Questionnaire Revised Short
Scale; BIS-11, Barratt Impulsiveness Scale.
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PES versus PCS behaviorally, which includes
factors genotype, drug, session, and type of
slowing (PES or PCS). Two separate MLM
analyses for the EEG data were set up, includ-
ing the factors genotype, medication, session,
and correctness for analysis of response-related
ERP amplitudes. The single-trial coupling be-
tween ERN amplitude and PES was subse-
quently analyzed in an MLM with the factors
genotype, drug, and session. Additional con-
trol analyses were run to ensure the presence of
expected task effects, and some more explor-
atory results are reported as described in the
corresponding results for completion. A com-
pound symmetric covariance structure was
chosen because it led to best model fits. Analy-
ses were calculated using SPSS version 22
(IBM), and interaction effects were further an-
alyzed by post hoc contrasts of estimated mar-
ginal means applying Bonferroni’s correction
implemented in SPSS.
Unspecific drug effects and control analyses. At the end of each session,
subjects filled out questionnaires and VASs again and completed a trail-
making task. This task served as a control to exclude detrimental effects of
citalopram on visuomotor coordination, and different versions were
used in the first and second test sessions. Citalopram did not prolong the
time needed for completion (citalopram, 59  2 ms; saline, 58  2 ms;
MLM, F(1,32) 1, p 0.59), and neither were genetic group differences
observed (F(1,32) 1, p 0.44).
Heart rate and blood pressure were measured immediately before the
intravenous cannula was placed (t0), when the infusion was completed
(t1), and three times thereafter (t2–t4). Analysis of these data showed a
small but robust increase of peripheral mean arterial pressure by citalo-
pram compared with saline (average of 4 mmHg) at t3 and t4 (both p
0.001), whereas heart rates remained unchanged, matching 5-HTs phys-
iologic characteristics (Veenstra-VanderWeele et al., 2000). Addition-
ally, no difference at baseline (t0) was seen (p 0.93).
VASs were used to assess differences in self-reported mood changes
and examined the factors calmness, alertness, and contentedness (Bond
and Lader, 1974). We then compared the differences in changes of self-
reports between baseline level (t0) and after the session (t4) between
citalopram and saline conditions in an MLM analysis. We observed a
trend for decreased calmness by citalopram administration (F(1,32) 
3.30, p 0.079) and no effects for the other two factors (p values0.20).
Exploratory post hoc contrasts showed that the effect on calmness was
numerically larger in the SS group (change,	0.81 0.48 cm, F(1,32)
2.79, p 0.104) than the LL group (change,	0.39 0.45 cm, F(1,32)
0.76, p  0.390), yet no significant interactions between genotype and
drug were observed for any item (p values0.50).
The state part of the state-trait anxiety index (STAI; Spielberger et al.,
1983) was used to assess differences in anxiety. Changes induced by the
drug were obtained by subtracting baseline levels before each test session
from the results attained at follow-up. MLM analysis of these scores
showed a trend toward larger pre–post differences in the saline condition
(F(1,32) 3.39, p 0.075), which was attributable to a decrease in scores
seen in the saline condition (
STAI  	1.4  0.7 points, 	2.6  2%
decrease relative to baseline), whereas scores remained constant under
citalopram (
STAI  0.3  0.7 points, 1.5  2% increase relative to
baseline). Neither the trend-level drug effect for calmness nor STAI
scores correlated with drug effects on the variables of interest of PES,
ERN, and error positivity (all p values0.18).
In summary, these data indicate that successful drug administration
and the observed trends are in accordance with effects of acute SSRI
administration that may increase restlessness or anxiety initially
(Burghardt and Bauer, 2013), possibly mediated by corelease of other
transmitters (Fischer et al., 2015), yet no severe side effects are seen such
that unspecific drug-related confounds could be ruled out.
Results
Behavioral effects
Main analysis
We calculated PES by subtracting median RTs on correct trials
after errors from those that did not follow errors (Fig. 2A). Trials
that represented double errors (i.e., were preceded or followed by
another error) were excluded. Additionally, we performed the
same calculation for trials that followed incongruent events,
which are also known to induce slowing on the following trial
(Ullsperger et al., 2005; Verguts et al., 2011) and submitted both
to MLM analysis with factor type of slowing (PES or PCS). This
analysis revealed a main effect for factor type of slowing, indicat-
ing higher slowing after incongruent events (18  2 ms) com-
pared with errors (10  2 ms). Furthermore, significant
interactions for type of slowing with drug (F(1,96)  7.8, p 
0.006) and genotype (F(1,32) 4.2, p 0.043) were seen. Post hoc
tests confirmed a significant drug effect on PES in which citalo-
pram increased slowing by 9  3 ms (F(1,96)  9.1, p  0.003),
whereas it led to a nonsignificant decrease of PCS (
RT,	3 3
ms, F(1,96)  0.9, p  0.35). Subjects carrying the SS genotype
showed higher PES (15 3 ms) than subjects with LL genotype
(5  3 ms, F(1,55.8)  5.0, p  0.029). No difference between
genetic groupswas seen for PCS (
RT, 0.6 4ms,F(1,96) 1, p
0.88). The drug effect did not depend on the genotype (interac-
tion of genotype drug and genotype drug type of slowing,
both F  1 and p  0.5). These results indicate that slowing
induced by errors but not conflict was specifically increased by
citalopram and that SS subjects with presumably higher 5-HTT
expression also display more slowing.
Control analyses
A confirmatory MLM analysis of overall median RTs in the task showed
trends for higher RTs under citalopram (360  3 ms) than the saline
condition (354 3ms, F(1,32) 3.3, p 0.077) and toward faster RTs for
subjects with genotype LL (351 4 ms) than SS (362 5 ms, F(1,32)
3.45, p  0.072). Neither the total number of errors (Fig. 2B) nor the
number of errors on incompatible trials was modulated by genotype or
drug (MLM, all p 0.20). Comparable with other studies, subjects in our
taskwere slower in themore difficult incongruent trials (
RT, 76 2ms,
p 10	10). Furthermore, subjects responded faster when they made an
erroneous response (
RT, 	90  2 ms, p  10	10). None of these
factors interacted with drug or genotype (all p 0.29).
Exploratory analyses
Across individuals, higher PES (but not PCS) correlated positively with a
post-error increase in accuracy (PIA;Danielmeier et al., 2011) in both the
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Figure 2. PES but not PCS is modulated by citalopram and 5-HTTLPR. A, PES is compared with PCS. We found amodulation by
5-HT only for slowing induced by errors but not conflict itself. Citalopram increased PES ( p 0.003), and SS subjects showed
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saline (r 0.45, p 0.009) and citalopram (r 0.48, p 0.005) condi-
tions (PCS, all p values 0.18), suggesting that PES provided time for
more task-specific post-error adjustments (Danielmeier and Ullsperger,
2011). However, accuracy after errors was not affected by any 5-HT-
related factor (all p values0.1). This can in part be explained by the high
variability (range, 1–21) and the low average number of double errors
(6 0.62), rendering this an insensitivemeasure. Additionally, we found
no 5-HT-related effects on post-error reduction of interference, PIA it-
self, or the conflict-adaptation effect (all p values 0.1 for drug, geno-
type, and their interaction; Gratton et al., 1992).
Main EEG analysis
After artifact correction, on average, 43 incompatible error trials
(range, 26–52) per subject remained after double errors were
excluded. ERN and correct-related negativity (CRN) amplitudes
were measured as the negative peak between 0 and 100 ms at
electrode FCz akin to the first study reporting an effect of
5-HTTLPR on ERN amplitudes (Fallgatter et al., 2004; Fig. 3).
MLM analysis confirmed a highly significant effect for factor trial
type (error, correct) on EEG amplitudes (error 
V, 	10.5 
0.5, F(1,81) 445, p 10
	10), but neither were effects for factors
drug and genotype nor their interaction observed (all F values
0.1, p values 0.75). Exploratory contrasts within error trials
revealed no effect for drug (F(1,31)  1, p  0.37) or genotype
(F(1,31) 1, p 0.96) and no interaction (F(1,31) 1, p 0.90; for
exact values, see Table 2), and neither were significant effects
observed on correct trials for factors drug (F(1,31) 1, p 0.42),
genotype (F(1,31) 1, p 0.92), or their interaction (F(1,31) 1,
p  0.35). Amplitudes of the error positivity, measured as the
maximumpeak between 100 and 350ms at Cz, where amplitudes
were highest, were again not modulated by genotype (F(1,31) 1,
p 0.44) or drug (F(1,31) 1, p 0.29; interaction, F(1,31) 1, p
0.88).
Furthermore, ERP peak latencies did not differ depending on
any 5-HT-related factor for ERN (p values 0.42) and error
positivity (p values 0.65). The variance in ERN latencies was
somewhat larger in the LL group in the saline (mean  SD: LL,
61 21ms; SS, 66 16ms) and citalopram (LL, 60 18ms; SS,
64 14 ms) conditions.
Single-trial regression results
Using multiple robust regression analysis of single-trial ERN and
following post-error RT, we first sought to establish the link be-
tween EEG data and PES across all subjects by testing regression
coefficients collapsed over the repeated factor (drug) against
zero. This revealed negative covariations in the ERN time win-
dow (ERN peak, 34 ms; t test against 0, t(30)	4.33, p 0.0046
cluster-based permutation test; Fig. 4A), indicating that themore
negative the ERNon a single-trial level was, the higher the follow-
ing RT was; this pattern is in accordance with other studies (De-
bener et al., 2005;Wessel andUllsperger, 2011). Furthermore, the
opposite effect was observed for error positivity amplitudes, in
which a positive covariation was observed (error positivity peak,
146 ms; t(30) 3.66, p 0.027, cluster-based permutation test).
This suggests that ERN and error positivity both are sensitive for
single-trial variation and adjust subsequent slowing, likely to
provide time for adjustment. No significant interaction depend-
ing on the congruency of the following trials was found.We then
established the effects of drug and genotype by submitting regres-
sion coefficients (measured as response-lockedminima of regres-
sion coefficients between 0 and 100 ms) to MLM analysis. This
revealed a significant drug  genotype interaction: for subjects
Table 2. ERPmeasurements
ERN (V) CRN (V) Error positivity (V)
SS saline 	9.01 1.0 1.15 0.8 11.66 0.9
SS citalopram 	9.49 1.3 1.05 0.9 10.91 0.9
LL saline 	8.86 0.7 1.04 0.9 12.58 0.9
LL citalopram 	9.43 0.8 1.49 0.7 12.14 1.3
ERN and CRN were measured as the individual average minima between 0 and 100 ms after response onset at
electrode FCz (SEM). The error positivity was quantified as the individual averagemaxima between 100 and 350
ms after response onset at electrode Cz. Neither measure was modulated by acute SSRI administration, 5-HTTLPR
genotype, or their interaction.
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Figure 3. Citalopram and 5-HTTLPR do not affect ERN, CRN, or error positivity. Electrophysiological indices of performance monitoring were not significantly different between genetic and
pharmacological conditions. A, B, Drug effects within both genetic groups. C, The unmedicated genetic comparison. D, E, Scalp topographies at peak latencies for ERN and error positivity,
respectively, for all genotype and drug conditions, which do not indicate differences between genotypes or medication states. Shaded plots and error bars reflect SEM.
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homozygous for the L allele, citalopram significantly decreased
the covariation between ERN and following RT (
b	0.55
0.19, F(1,31) 7.82, p 0.009) which was not observed for sub-
jects homozygous for the S allele (
b 0.09 0.20, F(1,31) 1,
p 0.638; interaction drug genotype, F(1,31) 5.22, p 0.029;
Fig. 4B). No other main effects or interactions were significant
(all p values 0.12), and no drug or genotype effects were ob-
served for the following error-positivity-related covariation that
was revealed in the initial analysis (measured as maximum re-
gression coefficients between 100 and 200ms, all p values0.14).
Supporting EEG analyses
To increase confidence in the reported null effect on ERN ampli-
tudes and decrease the likelihood of amethodological problem in
ERP quantification that prevented us from finding a true effect,
we report here additional results that were obtained by different
ways of ERP quantification, inclusion of more trials, accounting
for general subjective amplitude variance, and an analysis ofmid-
frontal theta power.
First, we used the average ERN amplitude in the 20 ms sur-
rounding the grand-average peak (64 ms) instead of the individ-
ualminimum amplitude, whichmay be amore sensitivemeasure
because it reduces group variance. However, we did not observe a
drug (F(1,31) 1.83, p 0.19), genotype (F(1,31) 1, p 0.54), or
an interaction (F(1,31) 1, p 0.72) effect. Although none of the
comparisons were significant, the pattern of ERN results resem-
bled those on PES (LL saline,	6.8 0.7V vs SS saline,	7.6
0.8 V, p  0.472 genetic comparison without drug; LL citalo-
pram, 	7.6  0.7 V; SS citalopram, 	8.1  0.8 V). Results
were not changed when all errors, instead of only errors on in-
compatible trials, were included into the analysis.
The choice of baseline can influence results of peak- and
average-amplitude measures. Furthermore, baseline amplitudes
in response-locked analyses can be confounded by other factors
(e.g., RT). Thus, we repeated the analysis by applying a baseline
correction to the response-locked data that was derived from the
prestimulus activity of each trial (	300 to	100 ms) and always
fell into the response–stimulus interval. The apparently more
sensitive mean ERN measure (54–74 ms) showed no effect of
drug (F(1,31)  1, p  0.44), genotype (F(1,31)  1, p  0.86), or
their interaction (F(1,31) 1, p 0.93). Finally, we also normal-
ized measured ERN amplitudes by the average root mean square
baseline prestimulus power, which thus should account for
possible, especially morphological, intersubject differences.
However, neither for minimum (p values0.16) nor mean (p
values 0.2) ERN amplitudes were 5-HT-related effects
observed.
We also investigated genetic and pharmacological effects on
midfrontal theta power. Therefore, we applied current source
density transformation (Kayser and Tenke, 2006) to the EEG
signal, which was then convolved with a series of complexMorlet
wavelets between 3 and 40 Hz in 37 linear steps using a wavelet
width of 4.5 cycles. Prestimulus (	300 to 	100 ms) baseline
powerwas subtracted fromeach response-locked epoch, anddata
were thereafter scaled by the average power in the baseline range
to reflectmultiples of baseline activity. Because power can only be
positive and thus noise likely skews results to be larger when trial
numbers are lower, the trial numbers between all subjects and
across erroneous and correct responses (trials chosen as de-
scribed above)were reduced to the number of the lowest category
(26 trials) by randomly discarding the other trials. Theta power
was then derived by collapsing power from 4 to 8 Hz and mea-
sured as the average power from 	100 ms until 300 ms around
the response at electrodes FCz and Cz. At both electrodes and
within all genotype and drug conditions, theta power was signif-
icantly larger on error (FCz: average, 616  25% of baseline)
compared with correct trials (FCz: average, 284  19% of base-
line, all p  10	6). However, we observed neither a genetic or
pharmacological nor an interaction effect on midfrontal theta
power (all p values for both electrodes0.1).
Session effects
We found that overall RTs were shorter when subjects performed
the task for the second time (F(1,32) 9.90, p 0.004). Further-
more, PES decreased from 16 ms in the first session to only 4 ms
in the second session (F(1,32) 12.76, p 0.001). No interactions
involving the factors genotype or drug were significant (all p
values0.19). The number of errorswas notmodulated by factor
session (F(1,32)  1, p  0.82, average n errors for session 1 
63.1  1.9 and for session 2  63.5  1.9). Also, PCS was not
Figure 4. Relationship between ERN, error positivity, and PES via multiple robust regression. A, During the time window of the ERN, a significant negative covariation between single-trial EEG
in error trials and their respective following RTwas observed, indicatingmore slowingwhen ERN amplitudeswere higher (cluster-based permutation test, p 0.0046). The opposite pattern is seen
in the time window of the error positivity ( p 0.027) in which slowing increases when amplitudes become more positive. Data here are collapsed over drug conditions, and gray areas mark
significant time windows with p 0.01 uncorrected. B, A significant decrease in the covariation between single-trial ERN and consecutive slowing was seen for LL ( p 0.009) but not SS ( p
0.638) subjects when comparing saline and drug condition. Shaded plots and error bars reflect SEM.
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significantly reduced in the second session (first session, 20  2
ms; second session, 16 2 ms; F(1,32) 3.33, p 0.078; interac-
tion type of slowing  session, F(1,96)  3.5, p  0.065). This
indicates that subjects increased their performance when they
were more acquainted with the task indicated by lower RTs and
constant error rates and also seemed to be able to decrease PES
but less so PCS. This highlights the importance of accounting for
session effects in repeated-measures designs, even for tasks that
do not involve learning of task structures. For EEG measures,
error positivity (	1.65 0.71 V, F(1,31) 10.3, p 0.003) and
CRN (1.29 0.49V, F(1,31) 10.6, p 0.003) amplitudes were
reduced when the task was performed the second time. No effect
of task repetition was observed for ERN amplitudes (F(1,31) 1,
p 0.61). In accordance with the observed PES reduction in the
second session, although no ERN reduction was observed, we
also found a session effect in that covariation between EEG and
RTwas reduced when the task was repeated (
b	0.40 0.14,
F(1,31) 7.81, p 0.009).
Discussion
The aim of this study was to investigate the relationship and
specificity of 5-HT to error-related aversive inhibition and its
electrophysiological correlates. We found pharmacological and
converging genetic evidence that higher 5-HT levels are associ-
ated with increased PES, yet no ERP effect was found.
Acute intravenous low-dose SSRI administration led to in-
creased PES across genetic groups without affecting conflict-
induced slowing. SSRIs block the 5-HTT, which prevents 5-HT
reuptake and leads to increased 5-HT levels inmost brain regions
as evidenced via microdialysis (Beyer and Cremers, 2008), al-
though one recent study suggests that especially cortical regions
may show the opposite effect (Selvaraj et al., 2012). Furthermore,
SS subjects displayed higher PES compared with the LL group,
which fits well to the notion that this genotype displays higher
extracellular 5-HT levels attributable to lower 5-HTT expression,
as has been demonstrated in mouse models of 5-HTTLPR
(Mathews et al., 2004; Murphy et al., 2008). Although the link
between in vitromRNA 5-HTT expression and in vivomeasures
of 5-HTT binding (Jedema et al., 2010; Murthy et al., 2010) has
been highly debated, many studies report differential responses
to perturbations in 5-HT neurotransmission depending on
5-HTTLPR genotype (Roiser et al., 2006;Markus and Firk, 2009).
This suggests that, at least in part, genetic factors influence ongo-
ing serotonergic neurotransmission. Thus, the pharmacological
effect suggests a positive relationship between 5-HT levels and
behavioral adaptation after subjectively aversive events, and this
effect is compatible with the observed genetic effect. However,
given the difficulty in replicating previous genetic studies (NCI-
NHGRI Working Group on Replication in Association Studies,
2007), the latter finding clearly requires replication in an inde-
pendent sample.
These data fit well to ideas in which 5-HTmediates behavioral
inhibition only in the context of aversive events, likely to prevent
the repetition of maladaptive behavior (Dayan and Huys, 2009;
Boureau andDayan, 2011; Cools et al., 2011), whereas it has been
noted that serotonergic influences on inhibition are usually min-
imal when measured in unrewarded contexts in both humans
and animals alike (Winstanley, 2011). However, there is an on-
going discussion as to how 5-HT achieves this effect. Some stud-
ies suggested that 5-HT mediates the subjective effect of aversive
events. This idea ismainly based on genetic evidence in which the
5-HTTLPR S allele has been identified as a risk factor for depres-
sion after aversive life events (Caspi et al., 2003) that could be
mediated by an overactive aMCC-dependent performance mon-
itoring system (Holmes et al., 2010; Drabant et al., 2012). Sup-
porting this idea, one study by Fallgatter et al. (2004) reported
increased ERN amplitudes for S allele carriers, yet a replication
attempt failed (Olvet et al., 2010). Therefore, evidence for a link
between the serotonergic system and EEG correlates of error-
related functions is weak.
Another suggestion is that 5-HT does not mediate the actual
effect of aversive events or general behavioral inhibition but
rather the link between them both (Dayan and Huys, 2008;
Crockett et al., 2009). Crockett et al. (2012) showed that acute
dietary tryptophan depletion (ATD), a method that lowers sero-
tonergic neurotransmission, abolished response slowing in the
context of punishment predicting stimuli in a reinforced catego-
rization task. ATD also reduced the inhibitory effects of aversive
pavlovian cues on instrumental choices and impaired the ability
to passively avoid unfavorable stimuli by increasing active re-
sponding (Geurts et al., 2013). Furthermore, optogenetic stimu-
lation of serotonergic neurons in mice increased the ability to
withhold responding to obtain a primary reward without affect-
ing locomotion (Miyazaki et al., 2014). Additionally, studies in-
vestigating serotonergic effects on instrumental choices suggest
increased lose-switch behavior associated with the L allele (den
Ouden et al., 2013) and increased resilience to negative feedback
after high SSRI doses in rats (Bari et al., 2010). These findings
appear in line with the observed increase in PES reported here
because less deliberation time may lead to less optimal choices.
Furthermore, the absence of 5-HT effects on electrophysiological
indices of error detection arewell compatiblewith the notion that
5-HT mediates the link between aversive events and inhibition,
because these ERPs themselves likely do not reflect this transition
into behavioral adaptation.
It should be noted that, although human studiesmostly found
evidence for a role of 5-HT in promoting inhibition specifically
when punishment was expected (Crockett et al., 2012; Geurts et
al., 2013) or had to be predicted (Cools et al., 2008; Robinson et
al., 2011), electrophysiological (Miyazaki et al., 2012b) and recent
optogenetic evidence from rodent studies (Miyazaki et al., 2014)
indicate that 5-HT may be involved in inhibition to avoid pun-
ishment but also to obtain a reward. Furthermore, interfering
with serotonergic signaling of optogenetically targeted raphe
neurons decreased behavior that required maintenance of moti-
vation (Liu et al., 2014). Thus, another possible explanation for
the main physiologic role of 5-HTmay be to increase patience—
before inhibiting or activating to avoid punishment or achieve a
reward (Miyazaki et al., 2012a).Our data are compatible with this
proposal of serotonergic functioning because it could be interpreted
as an increase in patience to avoid repetition of a mistake accompa-
nying increased 5-HT levels. However, more experiments that spe-
cifically orthogonalize aversive andappetitive factorswith inhibition
andmaintenance of activity are highly desirable.
The behavioral effects on PES emerged in the absence of dif-
ferences in subjective estimates of self-reported affect in response
to errors, compatible with other studies (Hariri et al., 2002; Hol-
mes et al., 2010) and in accordance with absence of effects on
ERN and error positivity, which are assumed to be sensitive to-
ward the functional significance or salience of an error (Falken-
stein et al., 2000). This further suggests that 5-HT mediates
inhibitory effects independent of subjective appreciation of er-
rors and possibly the cortical performance monitoring network.
Certainly the current study is not sufficiently powerful to finally
rule out an association between ERN or error positivity and
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5-HT,whichmaybe found in larger samples.However, it shouldbe
noted that, even when very sensitive measures of ERN amplitudes
were post hoc explored, neither drug nor genetic effects approached
trend levels. Especially the absence of a drug effect in a powerful
repeated-measures designwithwell controlled intravenous drug ap-
plication and control for the genetic background suggests indepen-
dence of electrophysiological indices of error processing from the
5-HT system in accordance with other studies using orally ap-
plied SSRIs (de Bruijn et al., 2006; Barnes et al., 2013). Addition-
ally, it is unlikely that the drug dose used in the current study was
insufficient to induce effects. Even an oral dose of 10 mg of cita-
lopram has been demonstrated to block 65% of midbrain
5-HTTs via in vivo single-photon emission computed tomogra-
phy (Klein et al., 2006), and we observed clear behavioral and
cardiovascular effects. Thus, it seems that the neurogenerators
giving rise to ERN and error positivity are insensitive to acute
pharmacological perturbations and likely genetic variation in the
serotonergic system.
One may wonder how the behavioral 5-HT effects then arise.
When the link between error detection and translation into be-
havioral adaptation is investigated more directly, we found dif-
ferential effects of the drug in both genetic groups. For LL
subjects, the strength of coupling between ERN and consecutive
RT adjustments is decreased by SSRI administration, but this is
not the case for SS subjects. One could speculate that higher SSRI
doses may lead to interactive effects for other factors as well, for
example, when assuming an inverted U-shaped relationship be-
tween 5-HT and efficient functioning (Cano-Colino et al., 2014).
The decoupling of behavioral adaptation suggests an indepen-
dent mechanism that increases behavioral inhibition and does
not affect cortical EEG correlates. One may thus speculate that
the inhibition is implemented in subcortical structures, of which
especially the subthalamic nucleus (STN) seems a likely structure
to mediate PES (Cavanagh et al., 2014; Siegert et al., 2014). Fur-
thermore, the STN has long been known to receive strong sero-
tonergic projections from raphe nuclei, in which most of the
brain serotonergic neurons reside, and 5-HT injections into the
STN increased firing rates (Xiang et al., 2005). At least a subpop-
ulation of likely serotonergic raphe neurons code aversive signals
(Nakamura et al., 2008), which may mediate the observed slow-
ing effect.
Finally, the genetic findings of higher PES in the SS group also
highlight that, although the S allele may be a risk factor for mood
disorders, under certain circumstances, greater behavioral adap-
tation aftermistakesmay also be beneficial, because it can serve to
decrease the likelihood of repeating a mistake (Homberg and
Lesch, 2011). In line with this, we found a robust correlation
between PES and the increase of accuracy after errors, suggesting
that subjects in our task were more cautious in responding in
post-error trials, which effectively kept performance high (Dan-
ielmeier and Ullsperger, 2011).
In summary, the current study provides important new evi-
dence for a role of 5-HT inmediating rapid behavioral adaptation
after response errors in that higher 5-HT levels appear to increase
PES as evidenced by pharmacological effects that are corrobo-
rated by converging genetic findings. However, cortical electro-
physiological correlates of error processing appear unaffected by
serotonergic influences, and the behavioral effect may be medi-
ated subcortically. This provides strong evidence for a role of
5-HT as the link between aversive processing and resulting inhib-
itory effects. Clearly, more imaging and electrophysiological
studies are needed to elucidate the neural mechanisms underly-
ing 5-HT-mediated inhibition, especially on the level of brains-
tem activity and its association to aversive coding.
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